Treatment Patterns and Mortality Risk among Elderly Patients with Metastatic Triple Negative Breast Cancer in the United States: An Observational Cohort Study Using SEER-Medicare Data
Purpose:
Triple negative breast cancer is more aggressive than other breast cancer
subtypes and accounts for up to 20% of all breast cancers.
Despite the poorer prognosis, there are no approved targeted treatments
available and chemotherapy remains the only choice. We examined treatment
patterns and outcomes among elderly metastatic triple-negative breast cancer
(mTNBC) patients in routine clinical practice. Methods:Patients were
identified from the linked SEER-Medicare database between 1/1/2001 and 12/31/2013 and included de novo Stage IV (n = 776) and patients with distant metastasis followed an
initial diagnosis of Stage I-III
disease (n = 1851). Kaplan-Meier analyses and time-varying Cox proportional
hazards regression were used to assess overall survival (OS). Results:The mean age at
metastatic diagnosis was 77.6 years and 1259 (48%) patients received
chemotherapy. Compared to <70 year olds, ≥70 year olds had worse
References
[1]
Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians, 67, 7-30. https://doi.org/10.3322/caac.21387
[2]
Tesarova, P. (2012) Breast Cancer in the Elderly-Should It Be Treated Differently? Reports of Practical Oncology and Radiotherapy, 18, 26-33.
https://doi.org/10.1016/j.rpor.2012.05.005
[3]
O’Shaughnessy, J. (2005) Extending Survival with Chemotherapy in Metastatic Breast Cancer. Oncologist, 10, 20-29.
https://doi.org/10.1634/theoncologist.10-90003-20
[4]
Foulkes, W.D., Smith, I.E. and Reis-Filho, J.S. (2010) Triple-Negative Breast Cancer. The New England Journal of Medicine, 363, 1938-1948.
https://doi.org/10.1056/NEJMra1001389
[5]
Gonzalez-Angulo, A.M., Timms, K.M., Liu, S., et al. (2011) Incidence and Outcome of Brca Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer. Clinical Cancer Research, 17, 1082-1089.
https://doi.org/10.1158/1078-0432.CCR-10-2560
[6]
Carey, L.A., Perou, C.M., Livasy, C.A., et al. (2006) Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-2502.
https://doi.org/10.1001/jama.295.21.2492
[7]
Dent, R., Trudeau, M., Pritchard, K.I., et al. (2007) Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clinical Cancer Research, 13, 4429-4434. https://doi.org/10.1158/1078-0432.CCR-06-3045
[8]
National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guidelines in Oncology. In: National Comprehensive Cancer Network, Ed., Breast Cancer, Version 2, NCCN, Fort Washington, PA.
[9]
Hutchins, L.F., Unger, J.M., Crowley, J.J., et al. (1999) Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials. The New England Journal of Medicine, 341, 2061-2067.
https://doi.org/10.1056/NEJM199912303412706
[10]
Lewis, J.H., Kilgore, M.L., Goldman, D.P., et al. (2003) Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials. Journal of Clinical Oncology, 21, 1383-1389. https://doi.org/10.1200/JCO.2003.08.010
[11]
Mandelblatt, J.S., Hadley, J., Kerner, J.F., et al. (2000) Patterns of Breast Carcinoma Treatment in Older Women: Patient Preference and Clinical and Physical Influences. Cancer, 89, 561-573.
https://doi.org/10.1002/1097-0142(20000801)89:3<561::AID-CNCR11>3.0.CO;2-A
[12]
Harlan, L.C., Abrams, J., Warren, J.L., et al. (2002) Adjuvant Therapy for Breast Cancer: Practice Patterns of Community Physicians. Journal of Clinical Oncology, 20, 1809-1817. https://doi.org/10.1200/JCO.2002.07.052
[13]
Hebert-Croteau, N., Brisson, J., Latreille, J., et al. (1999) Time Trends in Systemic Adjuvant Treatment for Node-Negative Breast Cancer. Journal of Clinical Oncology, 17, 1458-1464. https://doi.org/10.1200/JCO.1999.17.5.1458
[14]
Gennari, R., Curigliano, G., Rotmensz, N., et al. (2004) Breast Carcinoma in Elderly Women: Features of Disease Presentation, Choice of Local and Systemic Treatments Compared with Younger Postmenopasual Patients. Cancer, 101, 1302-1310.
https://doi.org/10.1002/cncr.20535
[15]
Warren, J.L., Klabunde, C.N., Schrag, D., et al. (2002) Overview of the Seer-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population. Medical Care, 40, IV-3-18.
https://doi.org/10.1097/00005650-200208001-00002
[16]
Stokes, M.E., Thompson, D., Montoya, E.L., et al. (2008) Ten-Year Survival and Cost Following Breast Cancer Recurrence: Estimates from Seer-Medicare Data. Value Health, 11, 213-220. https://doi.org/10.1111/j.1524-4733.2007.00226.x
[17]
Lamont, E.B., Herndon, J.E., Weeks, J.C., et al. (2006) Measuring Disease-Free Survival and Cancer Relapse Using Medicare Claims from Calgb Breast Cancer Trial Participants (Companion to 9344). Journal of the National Cancer Institute, 98, 1335-1338. https://doi.org/10.1093/jnci/djj363
[18]
Davidoff, A.J., Tang, M., Seal, B., et al. (2010) Chemotherapy and Survival Benefit in Elderly Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 28, 2191-2197. https://doi.org/10.1200/JCO.2009.25.4052
[19]
Klabunde, C.N., Legler, J.M., Warren, J.L., et al. (2007) A Refined Comorbidity Measurement Algorithm for Claims-Based Studies of Breast, Prostate, Colorectal, and Lung Cancer Patients. Annals of Epidemiology, 17, 584-590.
https://doi.org/10.1016/j.annepidem.2007.03.011
[20]
Charlson, M.E., Pompei, P., Ales, K.L., et al. (1987) A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation. Journal of Chronic Diseases, 40, 373-383.
https://doi.org/10.1016/0021-9681(87)90171-8
[21]
Warren, J.L., Harlan, L.C., Fahey, A., et al. (2002) Utility of the Seer-Medicare Data to Identify Chemotherapy Use. Medical Care, 40, 55-61.
https://doi.org/10.1097/00005650-200208001-00008
[22]
Suissa, S. (2008) Immortal Time Bias in Pharmaco-Epidemiology. American Journal of Epidemiology, 167, 492-499. https://doi.org/10.1093/aje/kwm324
[23]
Du, X. and Goodwin, J.S. (2001) Patterns of Use of Chemotherapy for Breast Cancer in Older Women: Findings from Medicare Claims Data. Journal of Clinical Oncology, 19, 1455-1461. https://doi.org/10.1200/JCO.2001.19.5.1455
[24]
Newschaffer, C.J., Penberthy, L., Desch, C.E., et al. (1996) The Effect of Age and Comorbidity in the Treatment of Elderly Women with Nonmetastatic Breast Cancer. Archives of Internal Medicine, 156, 85-90.
https://doi.org/10.1001/archinte.1996.00440010103014
[25]
Muss, H.B., Woolf, S., Berry, D., et al. (2005) Adjuvant Chemotherapy in Older and Younger Women with Lymph Node-Positive Breast Cancer. JAMA, 293, 1073-1081.
https://doi.org/10.1001/jama.293.9.1073
[26]
Hayes, D.F., Thor, A.D., Dressler, L.G., et al. (2007) Her2 and Response to Paclitaxel in Node-Positive Breast Cancer. The New England Journal of Medicine, 357, 1496-1506. https://doi.org/10.1056/NEJMoa071167
[27]
Hugh, J., Hanson, J., Cheang, M.C., et al. (2009) Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the bcirg 001 Trial. Journal of Clinical Oncology, 27, 1168-1176.
https://doi.org/10.1200/JCO.2008.18.1024
[28]
Martin, M., Rodriguez-Lescure, A., Ruiz, A., et al. (2010) Molecular Predictors of Efficacy of Adjuvant Weekly Paclitaxel in Early Breast Cancer. Breast Cancer Research and Treatment, 123, 149-157. https://doi.org/10.1007/s10549-009-0663-z
[29]
Newcomb, P.A. and Carbone, P.P. (1993) Cancer Treatment and Age: Patient Perspectives. Journal of the National Cancer Institute, 85, 1580-1584.
https://doi.org/10.1093/jnci/85.19.1580
[30]
Iglesia, M.D., Vincent, B.G., Parker, J.S., et al. (2014) Prognostic b-Cell Signatures Using mrna-seq in Patients with Subtype-Specific Breast and Ovarian Cancer. Clinical Cancer Research, 20, 3818-3829.
https://doi.org/10.1158/1078-0432.CCR-13-3368
[31]
Nanda, R., Chow, L.Q., Dees, E.C., et al. (2016) Pembrolizumab in Patients with Advanced Triple-Negative Breast Cancer: Phase ib Keynote-012 Study. Journal of Clinical Oncology, 34, 2460-2467. https://doi.org/10.1200/JCO.2015.64.8931
[32]
Garcia-Teijido, P., Cabal, M.L., Fernandez, I.P., et al. (2016) Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clinical Medicine Insights: Oncology, 10, 31-39.
https://doi.org/10.4137/CMO.S34540
[33]
Wimberly, H., Brown, J.R., Schalper, K., et al. (2015) Pd-l1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunology Research, 3, 326-332.
https://doi.org/10.1158/2326-6066.CIR-14-0133
[34]
Dawood, S., Broglio, K., Ensor, J., et al. (2010) Survival Differences among Women with De Novo Stage IV and Relapsed Breast Cancer. Annals of Oncology, 21, 2169-2174. https://doi.org/10.1093/annonc/mdq220
[35]
Hassett, M.J., Ritzwoller, D.P., Taback, N., et al. (2014) Validating Billing/Encounter Codes as Indicators of Lung, Colorectal, Breast, and Prostate Cancer Recurrence Using 2 Large Contemporary Cohorts. Medical Care, 52, e65-e73.
https://doi.org/10.1097/MLR.0b013e318277eb6f
[36]
Nordstrom, B.L., Whyte, J.L., Stolar, M., et al. (2012) Identification of Metastatic Cancer in Claims Data. Pharmacoepidemiology and Drug Safety, 21, 21-28.
https://doi.org/10.1002/pds.3247
